3.1. Patient Characteristics and Efficacy of Atezolizumab
ADVERSE EVENT
A total of 100 patients were enrolled in this study, and 100 plasma and 100 buffy coat samples were obtained at C0 (The ORR and DCB rates were 10 and 25%, respectively (At the median follow-up of 12.3 months, the median PFS and OS of the ITT population were 2.1 months (95% confidence interval (CI): 1.6–3.0) and 13.1 months (95% CI: 10.1–16.2), respectively. Patients with high PD-L1 expression had a longer PFS compared with patients with a low-to-negative PD-L1 expression (Adverse events developed in 82 patients (